The manufacturer of a drug which could extend the lives of thousands of people suffering from a rare form of cancer has agreed to pay for further patient treatment as part of a cost-cutting scheme.
The company PharmaMar has announced it will meet the expense of the cancer drug, called trabectedin, if a patient needs it beyond a fifth cycle.
The decision by NICE means the lives of people suffering with advanced soft tissue sarcoma could be extended by at least three months.
Currently about 2,000 people a year are diagnosed with the disease in the UK, and in England and Wales between 500 and 600 people live with the cancer.
Trabectedin will benefit around 110 patients a year who have failed on other treatments, at a cost of more than £3,500 a cycle.